English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Oregon Psilocybin Law: What's Legal, What Isn't, and Why It Matters for Retreat-Seekers
A few years back, a small herbal shop in Portland made the kind of headlines that confuse the hell out of anyone trying to understand where psychedelics actually stand in the United States. People lined up around the block. They filled out questionnaires. They walked out with bags of psilocybin mushrooms — varieties with names like Penis Envy and Albino Golden Teacher — paying somewhere around $85 to $95 for seven grams. The shop framed itself as Oregon's first licensed psychedelic dispensary. It wasn't. Not even close. And the gap between what was happening on that sidewalk and what Oregon's psilocybin law actually permits is exactly the kind of confusion that trips up people researching plant medicine, master plants, and psychedelic retreats. If you're weighing whether to spend real money on a retreat, you need to understand this landscape clearly — because the difference between a legal therapeutic container and an unregulated transaction has real consequences for your safety, your wallet, and your healing. Oregon passed Measure 109 — the Oregon Psilocybin Services Act — back in November 2020. It was the first state-level psilocybin law of its kind in the country, and it was a genuine milestone for psychedelic-assisted recovery. But the measure didn't do what a lot of casual readers assume it did. It did not decriminalize mushrooms. It did not legalize recreational sale. It did not turn psilocybin into something you can pick up alongside your kombucha. What it created was a tightly regulated framework for supervised therapeutic use. Under Measure 109, psilocybin can only be consumed at a licensed service center, in the presence of a licensed facilitator, by someone who has gone through a preparation session. There is no take-home model. There is no retail counter. There is no path — present or planned — for buying mushrooms over the counter and walking out with them. Sam Chapman, who runs the Healing Advocacy Fund, put it about as plainly as anyone can: nothing in Measure 109, and nothing in any other Oregon law, permits the retail sale of psilocybin mushrooms. Not today, not in the future as the law is currently written. The state's licensed services exist because Oregonians dealing with depression, anxiety, and addiction stand to benefit from psilocybin — but only when the therapy is delivered safely, with screening, integration, and a trained guide. The Shroom House situation is a useful case study in what happens when commercial momentum runs ahead of regulation. Customers were asked to join a so-called "Shroom House Society," show two forms of ID, prove they were over 21, and fill out a questionnaire that asked about mental health history. From a distance, that paperwork looks vaguely clinical. Up close, it's a loyalty card with extra steps. A reporter who walked in was apparently buying within five minutes of finishing the form. A former employee eventually went to local news and said management had told staff the shop was the first medically sanctioned psychedelic retailer in the state. It wasn't. The Oregon Health Authority hadn't even started issuing facilitator and service-center licenses yet. The shop was operating in a legal vacuum that didn't actually exist — psilocybin is still a Schedule I substance under federal law, and at the time, no Oregon entity had authority to sell it commercially under state law either. The honest takeaway here isn't outrage. It's the recognition that wherever there's genuine therapeutic demand and unclear regulation, opportunists will find the seam. For anyone researching psychedelics seriously — especially anyone hoping to use them for addiction or depression — knowing the difference between an above-board therapeutic container and a guy with a storefront is essential. Compare the Portland storefront with what an actual psychedelic retreat involves and the contrast becomes obvious. Whether we're talking about psilocybin services in Oregon, ayahuasca ceremonies in the Peruvian Amazon, ibogaine in Mexico, or San Pedro in the Andes, the legitimate end of this world shares a common shape: None of that is what happens when you buy mushrooms over a counter and take them home. That's not a retreat. That's not therapy. That's a transaction, and any framing that suggests otherwise is doing the medicine — and the people it might help — a disservice. The honest answer is: increasingly, the evidence says yes — but the conditions matter enormously. Clinical research on psilocybin for alcohol use disorder, ibogaine for opioid dependence, and ayahuasca for various substance and behavioral addictions has been quietly accumulating for two decades now. The trial results aren't fringe anymore. Johns Hopkins, NYU, Imperial College London — serious institutions are publishing serious data on psychedelic-assisted recovery, and the early signal is that these compounds can interrupt patterns that years of conventional treatment couldn't budge. That said, master plants and synthetic psychedelics aren't magic. They're powerful tools that work best when held inside a real therapeutic process. Someone in active addiction who buys mushrooms at a storefront and dips in alone is not running the same intervention as someone going through a screened, prepared, facilitated session. The substance might be identical. The outcome rarely is. Set and setting — that old Leary phrase — turns out to be more than a slogan. It's most of the medicine. This is why the legal framework Oregon is building, slow and frustrating as it can feel, actually matters. A regulated facilitator model creates the conditions under which psilocybin's therapeutic potential can show up reliably. A storefront free-for-all creates the conditions under which people get hurt and the whole movement gets a black eye. Here's the practical takeaway. If you're someone quietly considering plant medicine — for a stuck depression, a trauma you can't seem to metabolize, an addiction that has outlasted every other intervention — the Portland story is a useful warning. The space is filling up with operators whose understanding of safety ranges from excellent to nonexistent. Marketing language and clinical legitimacy are not the same thing. A few things worth checking before you commit money or travel: The psychedelic-assisted recovery field is in a strange adolescent phase right now. The laws are catching up unevenly. The science is racing ahead. And in the gap between the two, both genuine healing centers and outright opportunists are setting up shop. Your job as a researcher — and a potential participant — is to tell them apart. If you've read this far and want to keep exploring legitimate options, a range of vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.
Vancouver's Magic Mushroom Dispensaries: Civil Disobedience or Legalization Strategy?
Walk down certain blocks of East Vancouver and you'll spot something that probably shouldn't exist under federal law: storefronts openly selling psilocybin. Chocolates, capsules, dried caps in glass jars. No back rooms, no whispered passwords. Just a counter, a price list, and a clerk who'll happily explain the difference between a microdose and what they call a “heroic” one. It's strange. It's a little brazen. And if you've been following the slow, uneven march of psychedelics from underground curiosity to clinical research darling, it's also very, very familiar. Because this exact playbook — open a shop, dare the authorities to shut you down, force the conversation — is how Canada ended up legalizing cannabis. Now a handful of activists are running the same experiment with magic mushrooms, and the rest of us get to watch in real time. Psilocybin is a controlled substance under Canadian federal law. Selling it is illegal. And yet, in Vancouver, a small but growing cluster of dispensaries does exactly that — out in the open, with signage, social media accounts, and customer reviews. The most visible operator is Dana Larsen, a longtime drug-policy activist who runs the Medicinal Mushroom Dispensary out of the same space as his Coca Leaf Café. He started selling psilocybin chocolates and capsules to walk-in customers a few years back, and he's been pretty transparent about his strategy: keep selling, get noticed, force the government to either crack down hard or move toward regulation. So far the government has done neither, which is its own kind of answer. Other shops have followed. Some opened during the pandemic to make up for lost revenue from cannabis or other businesses. A few are run by people who genuinely believe psilocybin should be available for therapeutic use and are tired of waiting for Ottawa to catch up. The Vancouver Police have said mushroom prosecutions aren't a top priority. City Hall has sent some sternly worded letters. The shops are still open. Here's the thing about Vancouver: this city has been a testing ground for drug-policy civil disobedience for decades. Illegal cannabis dispensaries operated openly there from at least 2015, with the city eventually creating a municipal licensing system — even though selling weed was still federally illegal at the time. Three years later, Canada legalized recreational cannabis nationwide. Was that legalization the direct result of grey-market shops? Probably not entirely. But the shops normalized the conversation. They made it impossible for politicians to pretend the demand wasn't there. They gave the public a chance to see, for years, that the sky didn't fall. By the time Parliament got around to writing legislation, the cultural battle was largely over. The mushroom dispensary owners are betting the same dynamic will play out again. The bet isn't crazy. Psilocybin research is moving fast — clinical trials at major universities, Health Canada granting individual exemptions for people with terminal illness or treatment-resistant depression, and a steady drip of mainstream media coverage that treats the molecule as medicine rather than menace. The legal frame is wobbling. Someone was always going to push. Let's pause on the medical claim, because it matters. There's now a real body of clinical evidence suggesting that psilocybin — typically administered in larger, supervised doses alongside psychotherapy — can produce meaningful and sometimes lasting reductions in depression and anxiety, including for people who haven't responded to standard treatments. It's also being studied for addiction, end-of-life distress, and a handful of other conditions where the conventional pharmaceutical toolkit has been underwhelming. This isn't fringe stuff anymore. It's published in peer-reviewed journals. It's drawing real money into psychedelic biotech. A psychedelic-focused exchange-traded fund launched on a Canadian exchange a few years ago, which is roughly the most boring possible signal that a thing has gone mainstream. Microdosing — taking sub-perceptual amounts on a regular schedule — is a different story. The popular case for it has run well ahead of the data. Some researchers find modest mood and creativity effects; others find that most of what people report is placebo. If you're considering microdosing for a specific mental health issue, the honest answer is: the jury's still out, and a properly supervised larger-dose session may have far stronger evidence behind it. Even with the shops operating openly, psilocybin remains illegal to sell or possess in Canada outside narrow exemptions. Health Canada does grant individual access through its Special Access Program, and there's a Section 56 exemption pathway, but both processes are slow, paperwork-heavy, and require specific medical circumstances. A not-for-profit called TheraPsil has spent years helping patients — especially those facing terminal diagnoses — navigate the bureaucracy. Many people give up and turn to grey-market shops or underground guides instead. In the United States, the picture is more fragmented. Federally, psilocybin is Schedule I. But Oregon has rolled out a regulated psilocybin services program, Colorado has decriminalized personal possession and is building out its own framework, and a growing list of cities — Denver, Oakland, Seattle, Detroit, several others — have effectively deprioritized enforcement. None of this makes it legal to buy mushrooms at a shop the way Vancouverites can. But the legal terrain is shifting fast enough that anything written about it has a short shelf life. If you've read this far, there's a decent chance you're not just curious about Canadian drug policy. You're weighing whether a psychedelic experience — mushrooms, ayahuasca, something else — might actually help with something specific. Depression that won't budge. A drinking problem. Grief. A sense that you've been on autopilot for years and can't find the off switch. A few honest things to consider before you walk into any dispensary or book any retreat: Vancouver's mushroom shops won't be the last act in this story. Whether they get raided, regulated, or quietly absorbed into a future legal framework, they've already done some of the work activists wanted them to do — they've made psilocybin visible, debatable, and increasingly unavoidable as a policy question. Other cities will follow. Some governments will move quickly; others will dig in. For individuals trying to figure out whether plant medicine has a real role in their own life, the better path is usually slower than walking into a shop. It involves reading widely, talking to people who've done the work, screening yourself for real medical risks, and choosing a setting with trained facilitators and a clear integration plan. Retreats — especially ones in jurisdictions where the practice is legal or traditionally protected — remain the most evidence-supported way most people access these experiences. If you're starting that research, a range of curated psilocybin and plant-medicine retreats can be explored on our marketplace here. The Vancouver dispensaries are an interesting symptom of where the culture is going. They're probably not where your own story should start.
The Psychedelic Industry Boom: What It Means for Retreat-Seekers in 2026
Five years ago, if you mentioned psychedelics at a dinner party, the room split in two — half the table assumed you were a stoner, the other half pictured you barefoot in the Amazon. Today that same conversation might involve a venture capitalist, a clinical psychologist, and your cousin who just got back from a psilocybin retreat in Jamaica. The world has changed fast. For anyone weighing whether to book an ayahuasca retreat, try ibogaine for addiction, or sit with master plants for the first time, that shift matters. The landscape around plant medicine has matured — and so have the questions you should be asking before you hand over a deposit. This piece is for people doing that research right now: what the psychedelic boom actually means on the ground, what's hype, and what's worth paying attention to. A handful of years ago, you could count the publicly traded psychedelic companies on one hand. Now there are dozens, with billions in combined market capitalization and serious clinical trial pipelines for psilocybin, MDMA, DMT, ibogaine, mescaline, and LSD. Universities that wouldn't touch this research in the 1990s are running double-blind studies and publishing in mainstream journals. Compass Pathways, MAPS, atai Life Sciences, Usona — these names mean something now, even to people who don't follow biotech. What changed? Partly, the data caught up. Studies on psilocybin for treatment-resistant depression, MDMA for PTSD, and ibogaine for opioid addiction kept producing results that were hard to ignore. Partly, public attitudes softened. And partly — let's be honest — investors smelled money. The combination created a wave that's still building. For the retreat-seeker, this matters in two ways. First, more research means better safety knowledge and better integration protocols filtering down into the retreat world. Second, the surge of attention has attracted a lot of newcomers offering ceremonies they're not qualified to lead. The boom cuts both ways. People use these words like they're synonyms. They aren't. Decriminalization means you won't be arrested for personal use or possession — the substance is still technically illegal, but enforcement is deprioritized. Legalization means a regulated market exists: licensed producers, licensed providers, taxes, the works. Oregon broke ground by decriminalizing all drugs and creating a regulated psilocybin services program. Colorado followed with its own framework for psilocybin and other natural medicines. Several cities — Denver, Oakland, Detroit, Washington D.C. among them — have decriminalized plant medicines locally. Australia became the first country to formally allow psychiatrists to prescribe psilocybin and MDMA for certain conditions. The picture keeps shifting. Here's why this affects your decision: a legal psilocybin retreat in Oregon operates under very different conditions than an underground ceremony in California or a traditional ayahuasca retreat in Peru. Each has tradeoffs. Legal frameworks bring oversight and accountability but often strip out the ceremonial and traditional elements many seekers are specifically looking for. Underground and international retreats may offer deeper traditional practice but come with their own risks — legal, medical, and ethical. None of these is automatically better. They serve different needs. A combat veteran working through PTSD might benefit from a clinical setting. Someone wrestling with a long stuck pattern around grief or identity might find more in a traditional Amazonian dieta. Knowing the difference is half the work. Talk to enough facilitators and you'll notice the same themes coming up in intake calls. The people booking psychedelic retreats today aren't mostly seekers chasing a transcendent experience. They're mostly tired. They're tired of antidepressants that flattened them without fixing anything. Tired of years of talk therapy that helped but didn't move the deep stuff. Tired of drinking too much, scrolling too much, sleeping badly, snapping at their kids. Some are in real crisis — active addiction, suicidal ideation, treatment-resistant depression. Others are doing fine on paper but feel like they've been sleepwalking through their own life. Plant medicines and psychedelics have earned attention because, in many cases, they actually help with this stuff. Ayahuasca and ibogaine have a particularly strong track record around addiction recovery — not because the medicine "cures" anything in one sitting, but because it tends to interrupt the patterns that addiction lives inside. People describe seeing themselves clearly, sometimes for the first time in years. What they do with that clarity afterward is the whole game. The retreat industry has grown faster than its safety standards. That's the uncomfortable truth. A few things every serious researcher should know: If you've narrowed your interest to a specific medicine — ayahuasca, psilocybin, ibogaine, San Pedro, kambo — the next layer is choosing the right container. A short checklist that's served me well across years of writing about this space: If those questions get vague or defensive answers, that tells you something. If they get specific, thoughtful answers — even when the answers are honest about limitations — that tells you something different. FDA approval for MDMA-assisted therapy for PTSD has stalled and restarted more than once, and psilocybin therapy isn't far behind in the clinical pipeline. Within the next few years, it's plausible that one or two psychedelic-based medications will be available by prescription in the U.S. — under tight clinical conditions, at significant cost. That will reshape the conversation again. But the retreat world won't disappear. For many people, the medicalized version of psychedelic therapy — a clinic, a therapist, a controlled dose — won't deliver what they're actually looking for. There's a reason people fly to the Amazon to drink a bitter brew in a wooden maloca instead of taking a capsule in a beige office. The container matters. The tradition matters. The community around it matters. If you're at the point of seriously considering a retreat, the most useful thing you can do is slow down. Read more than the homepage. Talk to people who've sat with the medicine you're curious about. Get honest with yourself about what you're hoping for and what you're scared of. If something here speaks to you, the available ayahuasca and plant-medicine retreats can be browsed and booked on our marketplace here. This is a real decision with real stakes — both the upside and the downside. Treat it that way, and you'll be ahead of most people walking into ceremony.
Can Psychedelics Help Fighters Heal Brain Trauma? Inside the UFC's New Research Push
A retired fighter forgets his own children's names. He gets dizzy walking across the kitchen. Last week, he says, is a blur. This isn't a scene from a documentary about boxing in the 1970s — it's the reality being described, right now, by men who fought professionally less than a decade ago. And it's the reality that has pushed one of the biggest combat-sports organizations in the world to start asking a question that would have been unthinkable a few years back: could psychedelics actually help? The UFC has quietly opened the door to exploring psychedelic-assisted therapy as part of its broader brain-trauma research, and the implications stretch far beyond the octagon. If plant medicine can offer something for fighters carrying years of accumulated damage, what does that say about the wider potential of substances most of the world still classifies as illegal? It's a strange moment in the story of psychedelics — one where the conversation has moved from underground ceremonies to press conferences with cage fighters. The shift didn't happen in a vacuum. For years, former fighters have spoken in hushed tones about cognitive decline, mood collapse, suicidal ideation, and the personality changes that often arrive in their forties. The condition has a name — chronic traumatic encephalopathy, or CTE — and it's a problem the sport has been slow to address publicly. When a recent feature documented one former UFC competitor's diagnosis of permanent disability, with memory loss severe enough that he sometimes forgets which child he's speaking to, the conversation got harder to dodge. UFC president Dana White acknowledged the obvious in a follow-up interview: this isn't one fighter's misfortune. It's structural. Anyone who has done this long enough is dealing with something. He called it part of the gig — which is honest, even if it's bleak. What's new is that the organization has signaled it wants to do more than nod sympathetically. A multi-year extension of its partnership with the Cleveland Clinic, plus a substantial donation to the Lou Ruvo Center for Brain Health in Las Vegas, set the stage. Then White name-dropped the psychedelic researchers at Johns Hopkins, and suddenly the story changed shape. The trigger appears to have been a televised feature on retired professional athletes — football players, mostly — who turned to psilocybin and ayahuasca after their careers ended. They described relief from depression, from rage, from the suffocating fog that follows years of head trauma. Their stories aren't peer-reviewed, but they're not nothing either. They're the kind of testimony that makes institutions pick up the phone. The Center for Psychedelic and Consciousness Research at Johns Hopkins has spent the last decade and a half building a serious body of work on substances like psilocybin and LSD. They've published dozens of peer-reviewed papers covering addiction (nicotine, alcohol, and other dependencies), end-of-life anxiety in cancer patients, and treatment-resistant depression. The results have been striking enough that the FDA has granted breakthrough-therapy status to psilocybin for depression, which is not the kind of designation a regulator hands out casually. What we don't yet have — and this is important — is a robust body of evidence specifically on psychedelics for traumatic brain injury. The mechanisms researchers are excited about are suggestive rather than proven. Psilocybin appears to promote neuroplasticity, meaning the brain's capacity to form new connections. Some animal studies have shown growth in dendritic spines after a single dose. For a brain that's been concussed dozens or hundreds of times, the idea of a compound that might literally help neurons reorganize is, understandably, electrifying. But excitement isn't proof. The leap from "helps depressed patients" to "repairs cumulative head trauma" is enormous, and any honest researcher will tell you we're nowhere near making it confidently. What's happening now is the early-stage work of asking whether the question is even worth pursuing. The fact that a major sports body is funding part of that question is itself remarkable. Step back from the UFC story for a moment, because something larger is going on. Across North America, attitudes toward psychedelics have shifted with surprising speed. Oregon legalized supervised psilocybin use. Several cities have decriminalized natural psychedelics. Veterans' groups have become unlikely advocates for ibogaine and ayahuasca, citing dramatic relief from PTSD that conventional medication never delivered. The conversation that lived in Amazonian ceremony huts and underground therapy circles is now happening in legislatures, hospitals, and yes, mixed-martial-arts boardrooms. The plants and compounds at the center of this shift are sometimes called master plants by the traditions that have used them for centuries — ayahuasca, peyote, San Pedro, iboga, certain mushrooms. The term carries a specific meaning: these aren't recreational substances in the cultures that birthed their use. They're considered teachers, agents that show a person something about themselves they couldn't otherwise see. Whether you take that framing literally or metaphorically, it points at something the clinical research keeps confirming — these compounds tend to produce experiences that feel meaningful, and that meaning seems to be part of why they work. For someone recovering from addiction, the experience often involves seeing one's relationship to the substance with terrible clarity. For someone in depression, it can briefly dissolve the walls that the depressed mind builds around itself. For someone carrying trauma — including, perhaps, the kind of trauma a fighter accumulates — it may offer access to material the conscious mind has buried. None of this guarantees healing. But it changes what's possible. If you're reading this because you've been quietly researching plant medicine for your own reasons — not because you fight professionally, but because something in your life has gotten stuck — the UFC story matters in an indirect way. Institutional interest tends to drag taboos into daylight. When a sports organization openly explores psychedelic therapy, it gives cover to the doctor who's been quietly curious, the therapist who has clients asking about it, the family member who didn't know how to bring it up. The conditions where psychedelics have shown the most consistent results in trials so far include: The picture that emerges from these studies isn't of a miracle drug. It's of a tool that, used in the right context with the right preparation and integration, can produce shifts that years of conventional treatment couldn't. The right context matters enormously. A psychedelic dose taken in a clinical or ceremonial setting, with trained support before and after, is a completely different experience from the same dose taken alone at a music festival. The compound is the same. The outcome rarely is. People reading articles like this one often have a quieter question underneath: should I actually do this? It's worth being honest about what a retreat involves, because the romanticized version doesn't survive contact with the reality. A real ayahuasca or psilocybin retreat is physically demanding, emotionally raw, and occasionally terrifying. Participants vomit. They cry. They confront memories they've spent decades avoiding. The cliché of "sitting with your stuff" is accurate, and the stuff is rarely pleasant company. What separates a well-run retreat from a risky one isn't the location or the marketing — it's the people running it and the support structure around the medicine. A few things worth checking before you commit: The cost varies wildly — anywhere from a thousand dollars for a short domestic retreat in places where local laws allow, to ten thousand or more for longer stays in Peru, Costa Rica, or Mexico with extensive medical support. Expensive isn't automatically better. Cheap isn't automatically suspect. What matters is the fit between what's offered and what you actually need. It's worth pausing on how unlikely this moment is. A combat-sports organization, a major medical research center, indigenous traditions from the Amazon, neuroscientists at a top-tier university, and ordinary people quietly weighing whether to book a retreat — all of them, in different ways, are circling the same question. What if the substances we've spent fifty years criminalizing turn out to be among the most useful tools we have for the things modern medicine struggles most with? The answer won't be a clean yes. It will be messy, partial, and full of caveats. Some people will be helped enormously. Others won't be helped at all. A few will have bad experiences that take years to integrate. This is true of every powerful intervention, from surgery to antidepressants to long-term therapy. What's different about psychedelics is that the conversation around them has finally caught up with what practitioners and participants have been quietly saying for decades — they do something, and that something is worth taking seriously. For readers who feel drawn to take this further — whether that means deeper reading, a conversation with a knowledgeable guide, or actually exploring a structured experience — a range of curated ayahuasca and psychedelic retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. The medicine isn't going anywhere, and the choice deserves the same care the experience itself will demand of you.
Oregon's Psilocybin Law: What Legal Mushroom Therapy Actually Looks Like
When Oregon voters approved Measure 109, something genuinely strange happened in American drug policy. A state had, for the first time, said yes to supervised, legal use of a classic psychedelic — psilocybin, the active compound in magic mushrooms — outside any research or religious-exemption framework. Not decriminalization. Not a clinical trial. An actual licensed-services model. If you're someone weighing a psychedelic retreat for depression, addiction, trauma, or just a stuck life pattern you can't seem to shake, this matters. It changes the map. I want to walk through what Measure 109 actually does, what it doesn't do, and how it fits into the bigger conversation around psychedelics, plant medicine, and addiction recovery. Because a lot of what gets repeated online is half right at best. The short version: roughly 56% of Oregon voters approved the measure. It directed the Oregon Health Authority to build a regulated program — the Oregon Psilocybin Services Program — where licensed facilitators can administer psilocybin to adult clients inside licensed service centers. Manufacture, processing, delivery, and possession of psilocybin became legal under state law, but only inside that licensed framework. Step outside it and the old criminal penalties still apply. The measure also baked in a two-year development period before the program actually opened its doors. That wasn't bureaucratic foot-dragging. Oregon was building something nobody else had built — licensing categories, training requirements, dosing rules, packaging standards, an advisory board, a tax structure. The state essentially had to invent the rulebook from scratch. A few specifics worth knowing if you're trying to understand what's actually on offer: The timing wasn't random. For most of the last decade, research out of Johns Hopkins, NYU, and Imperial College London has been publishing results on psilocybin-assisted therapy for treatment-resistant depression, end-of-life anxiety, and substance use disorders that ranged from interesting to genuinely startling. A single high-dose session, in the right setting, with proper preparation and integration, was producing sustained improvements that conventional pharmaceuticals struggle to match. That's the research backdrop. The cultural backdrop is messier and more interesting. A generation that grew up being told mushrooms would melt their brains started reading clinical papers and noticing the science said something rather different. Veterans were talking openly about psychedelic healing. People in addiction recovery were saying ibogaine and psilocybin had done what twelve-step rooms and SSRIs couldn't. The conversation around master plants — the term Amazonian traditions use for teacher-plants like ayahuasca, San Pedro, and tobacco — was bleeding into the mainstream wellness world. Oregon's vote was, in a sense, the political system catching up with what a lot of people had already quietly concluded: that these substances, used carefully, are not the menace the 1970s told us they were. Here's where I'll be honest with you. Oregon's program is real, and it's legal, and it's a meaningful option. But it's not the same animal as a traditional plant-medicine retreat in Peru or Costa Rica, and it's not trying to be. If you've been reading about ayahuasca ceremonies in the Sacred Valley or ibogaine clinics in Mexico, the Oregon model will feel different — more clinical, less ceremonial, English-speaking, regulated. Which one is right for you depends on what you're actually after. A few honest distinctions: Whether you end up in Oregon, in the Peruvian jungle, or at a psilocybin retreat somewhere in between, the same red flags apply. The legalization wave has brought in serious practitioners and also, frankly, a fair number of opportunists. A few things to look for, and a few to run from. Good signs: a thorough medical and psychological intake before you ever pay a deposit. Clear questions about your medications (especially SSRIs, MAOIs, and lithium — these interact badly with several plant medicines). A facilitator who's been doing this for years, not months. Real integration support, not a goodbye hug and a flight home. Honest conversations about who shouldn't take part — people with personal or family histories of psychosis, certain heart conditions, or untreated bipolar disorder are usually screened out for good reason. Warning signs: vague pricing, no medical questionnaire, promises of guaranteed healing, facilitators who claim to be the reincarnation of someone, group sizes that feel more like festivals than ceremonies, no aftercare plan, no way to talk to past participants. Trust your gut on this. The people doing serious work tend to feel grounded and a little boring in their professionalism. The flashy ones are often the ones to skip. One thing I'd offer to anyone reading this because they're hurting — because the depression hasn't lifted, because the drinking is back, because something inside is asking for help — is that psychedelics are a tool, not a magic eraser. The research is real. The experiences can be genuinely transformative. People do come out of a single session with shifts that years of talk therapy didn't produce. And. The work afterward is its own thing. The session opens a door. Walking through it — changing habits, repairing relationships, building the life the medicine showed you was possible — that part still belongs to you. The best retreats know this and structure their programs around it. The worst ones sell you the door and forget the rest of the house. If you're sitting with this decision, take your time. Read the research. Talk to people who've done it. Get medical clearance if there's any question. And if something here has nudged you toward exploring further, a curated selection of psilocybin and broader plant-medicine retreats can be browsed on our marketplace here. The right retreat at the right time can be a hinge in a life — but only if you walk in with eyes open.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Psychedelic Medicine in 2026: How MDMA, Psilocybin, and Ketamine Are Reshaping Mental Health
Something strange has happened to the conversation around psychedelics. A decade ago, mentioning that you were curious about psilocybin or MDMA at a dinner party got you a raised eyebrow and a quick subject change. Now your cardiologist might bring it up. Your therapist almost certainly has an opinion. And somewhere in the FDA's review pipeline, drugs derived from compounds your parents were told would melt your brain are quietly inching toward approval. If you're reading this because you're weighing a psychedelic retreat — for depression, addiction, trauma, or just the sense that something inside you needs reorganising — it helps to understand the broader picture. Plant medicine and psychedelics aren't fringe anymore. They're being studied in serious clinical trials, prescribed off-label in clinics, and discussed in medical journals that wouldn't have touched the topic in 2005. Here's where things actually stand. Ketamine was the one nobody expected to lead the charge. It's an anesthetic. A club drug. A horse tranquilizer, depending on who's telling the story. And yet it became the first compound to crack open mainstream psychiatry's door to dissociative and psychedelic-adjacent treatments — largely because its antidepressant effects refused to be ignored. What makes ketamine different from the SSRIs most people have tried (and many have quit) is the mechanism. Traditional antidepressants work on serotonin and take weeks to do anything noticeable. Ketamine acts on the glutamate system, and the relief can arrive within hours. For people who've been suicidal, that speed isn't a marketing point — it's the difference between making it through the week and not. By 2026, ketamine clinics have spread across most major cities in the U.S. and Europe. Spravato, the esketamine nasal spray, is FDA-approved for treatment-resistant depression and increasingly covered by insurance. The catch? Ketamine therapy isn't cheap, the effects can wear off, and it works best when paired with real psychological integration — not just an IV drip and a Lyft home. MDMA — the compound most people know as ecstasy or molly — has spent the last decade being studied in some of the most rigorous psychiatric trials ever run on a Schedule I substance. The work has been led primarily by MAPS, the nonprofit that's been pushing this research uphill since the 1980s. The results have been striking. In Phase 3 trials, a significant majority of participants with severe PTSD no longer met diagnostic criteria after a course of MDMA-assisted therapy. We're talking about combat veterans, survivors of childhood abuse, first responders — people for whom standard treatments had failed for years, sometimes decades. The therapy isn't a pill you take home. It's three or so dosing sessions in a clinical setting, paired with months of preparation and integration work. The FDA's review process has been bumpier than advocates hoped. There have been setbacks around trial methodology and concerns about therapist conduct in some sessions. Approval, when it comes, will likely arrive with strict guardrails — specific clinics, certified providers, monitored protocols. But the direction of travel is clear: MDMA is moving from underground use into supervised medical practice, and it's doing so faster than most psychiatrists predicted. If you've been following psychedelic research at all, you've probably seen the brain-scan images — the ones showing how psilocybin appears to loosen the rigid patterns of activity that depression carves into the mind. The research keeps replicating. Compass Pathways has moved psilocybin through multiple trial phases. Universities from Johns Hopkins to Imperial College London have dedicated entire research centres to the work. What's interesting isn't just the efficacy data — it's the patient stories. People describe a single high-dose psilocybin session producing more therapeutic movement than years of weekly talk therapy. That's a remarkable claim, and it deserves the skepticism it gets. But the data keeps showing the same thing: meaningful, durable reductions in depression scores, often after just one or two sessions. A few things worth knowing if you're considering a psilocybin retreat or eventually a clinical treatment: Ayahuasca sits in its own category, partly because its origins are nothing like the pharma-driven story of ketamine or MDMA. It's a brew. It's been prepared by Amazonian peoples for centuries. It contains DMT and an MAO inhibitor that makes the DMT orally active, and the experience tends to be longer, more physical, and more emotionally demanding than psilocybin. Clinical research on ayahuasca is real but smaller in scale than the work on psilocybin or MDMA. Studies out of Brazil and Spain have shown promising effects for depression and addiction, particularly for people who've cycled through conventional treatments without success. Anecdotally, the retreat circuit has been processing thousands of people a year for over a decade, and the patterns that emerge are consistent: ayahuasca tends to show people what they've been avoiding. Sometimes that's healing. Sometimes it's brutal. Often it's both. For addiction specifically, the picture is genuinely interesting. Ibogaine, derived from the iboga shrub, has shown remarkable results interrupting opioid dependency — and ayahuasca has its own track record with alcohol and stimulant patterns. Neither is a magic cure, and both carry medical risks that require real screening. But for someone who's tried twelve-step, rehab, SSRIs, and CBT without lasting change, plant medicine sometimes offers a doorway nothing else has. Here's the honest part. The legitimacy of psychedelic medicine is rising fast, but that doesn't automatically make every retreat a good idea. The same renaissance that's producing rigorous clinical trials is also producing a lot of opportunists — places that took a weekend training course and now call themselves a healing centre. If you're researching seriously, here are the questions that actually separate good operators from sketchy ones: You don't need every answer to be perfect. You do need to feel that the people running the place take the work — and your safety — seriously. A retreat that promises healing without acknowledging risk is a retreat to walk away from. What's actually happening, underneath all the headlines about FDA designations and Peter Thiel-backed startups, is a slow correction. For most of the last century, medicine treated the mind like a chemistry problem and the soul like a category error. Psychedelics — whether you encounter them in a clinic or a jungle — refuse that division. They make people feel things, see things, remember things. Sometimes they make people confront things they spent years avoiding. That's not a pharmaceutical pitch. It's an old observation that ceremonial cultures have known for a long time, and that Western science is now slowly, grudgingly catching up to. The medications coming out of clinical trials will help a lot of people. So will the retreats happening in Peru, Costa Rica, and the Netherlands. They're different doors into related territory. If something in this article has sharpened your curiosity, a curated selection of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — this isn't a weekend you want to rush into, and the right container makes all the difference.
The Wall Street Bet on Short-Acting Psychedelics: What It Means for Patients
Picture a depression treatment that works in twenty minutes. Not weeks. Not a six-hour ceremony with a trained sitter and a playlist of Brian Eno. Twenty minutes, sublingual tablet under the tongue, back to your life by lunch. That's the bet a growing crowd of biotech venture capitalists is now placing on the next wave of psychedelics — and it's quietly reshaping what plant-medicine healing might look like for millions of people who never plan to set foot in a jungle. For the better part of a decade, most established healthcare investors stayed at arm's length from psychedelic startups. The science looked promising. The optics? Less so. But a handful of firms have stopped hedging, and the deals they're cutting tell you a lot about where mainstream medicine thinks this whole field is heading — and where it isn't. The first wave of publicly-traded psychedelic companies — think the ones developing synthetic psilocybin or pharma-grade ibogaine — chased the experience itself. Their drugs produced long, immersive sessions that required a trained therapist sitting bedside for four, six, sometimes eight hours. Beautiful in theory. A nightmare to scale. The new wave is different. Investors are now writing checks for compounds engineered around one ruthless question: how do you get the antidepressant effect without tying up a clinic room and a licensed practitioner for an entire afternoon? The answer, increasingly, is short-acting molecules — synthetic versions of 5-MeO-DMT (the famously intense compound found in certain toad secretions and Amazonian plants), or so-called non-hallucinogenic psychedelics that may rewire the brain without ever sending the patient on a trip at all. One Boston-based firm has been the loudest voice in this shift, putting money into a Dublin company working on a 30-minute-to-two-hour 5-MeO-DMT treatment for treatment-resistant depression, and another startup pursuing psychedelic-inspired drugs stripped of their hallucinogenic effects. More recently, the same investor incubated a new venture developing a sublingual 5-MeO-DMT tablet with effects expected to last just 15 to 20 minutes. That company launched with a $60 million Series A from a roster of mainstream healthcare funds — money that wouldn't have touched this space five years ago. Here's the uncomfortable math. A psychiatrist at a major academic center has estimated the U.S. might need tens of thousands of newly trained psychedelic-assisted therapists once these treatments hit the market. We don't have them. Training pipelines are years behind demand. And if every dose of psilocybin requires a six-hour appointment with two trained facilitators, the cost per patient quickly drifts into territory most insurance plans won't touch. So the investor logic goes like this: a 20-minute treatment fits inside an existing clinic visit. It can be administered by staff already on payroll. It doesn't require a special preparation week or a three-session integration arc. From a pure access standpoint — getting an effective treatment to the largest number of people — it's the difference between a boutique luxury and actual medicine. I'll be honest. Reading that, part of me cheers. Another part of me winces. Because the long sessions aren't just a logistical inconvenience — for a lot of people, the slow descent and the human presence are the medicine. Compressing the whole thing into a sublingual tablet may scale, but scaling and healing aren't always the same thing. If you're researching ayahuasca, ibogaine, or a psilocybin retreat right now — maybe because therapy hasn't worked, or because addiction has worn down everyone in your life including you — none of this biotech news is going to be available to you anytime soon. The clinical trials are early. FDA approval, if it comes, is years out. Insurance coverage is further still. In the meantime, retreats remain the only legal pathway in much of the world to access these compounds, and they offer something the pharmaceutical model probably never will: ritual, community, and time. That said, the pharma push matters even if you never take a clinical drug. Here's why: What it won't do is replace the retreat experience. A short-acting tablet in a beige clinic chair is not the same animal as three nights of icaros in a maloca, and anyone selling you on that equivalence is selling you something. This is the question I get asked the most, and the honest answer is: nobody fully knows yet. The master plants — ayahuasca, San Pedro, peyote, iboga — have been used in ceremonial contexts for centuries, sometimes millennia. The traditions around them include diet, song, prayer, and a relationship with a specific lineage. Strip out the alkaloid, synthesize it in a lab, deliver it in 20 minutes, and you have something pharmacologically similar but contextually unrecognizable. Some researchers argue the molecule does the heavy lifting and the ritual is decoration. Others — including a lot of facilitators who've sat with thousands of participants — would tell you the ritual is the medicine, and the compound is just the doorway. My read, after years around this work, is that both are partly right. The molecule opens something. What you do with what gets opened depends entirely on the container. A clinical setting offers safety, screening, and standardization. A traditional retreat offers depth, integration, and a framework of meaning that's hard to manufacture in a hospital. Different tools, different jobs. The mistake is pretending one makes the other obsolete. Of all the conditions being studied, addiction is where the case for psychedelic healing looks strongest — and where the gap between clinical trials and real-world need is widest. Ibogaine retreats in Mexico and Costa Rica have been quietly interrupting opioid addiction for years. Ayahuasca has a substantial body of evidence supporting its use for alcohol and stimulant dependence. Psilocybin trials at major universities have shown remarkable results for tobacco and alcohol use disorders. The biotech world is paying attention. But the drugs furthest along in trials are mostly aimed at depression and PTSD, because those markets are larger and the regulatory path is clearer. Addiction recovery — especially the kind that involves a long, difficult experience confronting your own patterns — may end up being one of the things the retreat world keeps doing better than the clinic, simply because the work doesn't compress neatly into 20 minutes. If you're reading this because addiction is the reason you're considering a retreat, a few honest things to keep in mind: The short version: the science is real, the money is finally flowing, and within the decade we'll probably have at least a few legal, clinically-approved psychedelic medicines. That's good news for access and good news for stigma. But it doesn't make the retreat tradition obsolete. If anything, the contrast between a 20-minute tablet and a multi-day ceremony will make people more aware of what each offers, and more able to choose the path that fits their situation. For some people, that path is a clinical trial. For others, it's months of preparation followed by a week in the Amazon. For a lot of folks, it's somewhere in between — microdosing, breathwork, integration circles, slow work over years. There's no single right answer, and anyone telling you otherwise hasn't sat with enough people on the other side of these experiences. If you're closer to the retreat end of the spectrum and want to see what's actually out there, a curated selection of ayahuasca, psilocybin, and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the version of you that's ready will know when it shows up.
Kambo Ceremony Deaths: What the Tragic Inquest Reveals About Frog-Medicine Safety
Here's something the Kambo brochures don't tell you. In March 2019, a 39-year-old woman named Natasha Lechner collapsed during a Kambo ceremony in a quiet home in Mullumbimby, on Australia's northern rivers. Within minutes she was frothing at the mouth, her lips going blue, her pulse fading. By the time anyone called an ambulance, it was too late. The coronial inquest that followed pulled back the curtain on what's quietly become one of the more popular — and least regulated — plant medicine practices riding the broader psychedelic and master plants wave: Kambo, the secretion of a giant Amazonian tree frog, applied through small burns to the skin. People take it for addiction, depression, chronic pain, and what they describe as a kind of spiritual reset. Most ceremonies pass without incident. Some don't. And the difference between those two outcomes is exactly what every reader weighing a retreat needs to understand before they sign anything. Kambo is the dried secretion of Phyllomedusa bicolor, the giant monkey frog of the upper Amazon. Traditionally used by tribes including the Matsés, Katukina, and Yawanawá, it's applied to small burns on the upper arm or leg — gates, practitioners call them — and absorbed directly through the lymph. Within seconds the body responds intensely: pounding heart, facial swelling, vomiting, sometimes diarrhea. The whole ordeal is over in twenty to forty minutes. It's not a psychedelic in the classic sense. You don't hallucinate. You don't dissolve into oneness with the cosmos. What you do get is a brutal physical purge that practitioners frame as detoxification on multiple levels — physical, emotional, energetic. People who swear by it describe a kind of clarity afterwards, a lifting of something heavy. Researchers studying the secretion have found a cocktail of bioactive peptides that affect blood pressure, immune response, and the gut. Whether any of that adds up to the healing claims is genuinely an open question. Read the inquest carefully and a pattern emerges that goes well beyond one tragic ceremony. Lechner had recently completed a Kambo practitioner course herself, through an outfit called the International Association of Kambo Practitioners. The woman who applied the Kambo on the day she died was a separate practitioner who didn't have a phone in the room, didn't know to call emergency services, and — in testimony that's hard to read with a straight face — described responding to her dying friend with “psychic SOS” and “downloading from ancestors.” Lechner had the Kambo applied to her chest. That's not where Amazonian tribes put it. The IAKP founder herself, who trained the original lineage in this case, confirmed that traditional placement is the arm or leg. Chest placement was introduced in the West by an acupuncturist who claimed to blend Kambo with Traditional Chinese Medicine meridian points — an innovation that has no traditional grounding and no safety data behind it. A cardiologist testified that Lechner likely died of a sudden cardiac event. So you have an unregulated medicine, a Western-invented application protocol, a practitioner without basic emergency preparedness, and a young healthy woman dead in a living room. None of those failures are inherent to Kambo. All of them are failures of the people and structures around it. That distinction is the whole game when you're choosing any plant medicine experience. People searching for ayahuasca retreats, ibogaine for addiction, or psilocybin therapy often encounter Kambo as part of the same general menu. Some Amazonian retreats offer Kambo as a preparation before ayahuasca ceremonies — the idea being that it clears the body and sharpens receptivity. Master plants, in the traditional Amazonian framework, are teachers; ayahuasca and tobacco are the famous ones, but the broader tradition includes a whole pharmacopeia, and frog medicine sits adjacent to it rather than within it. The crossover audience is significant. People drawn to psychedelic healing for addiction, depression, or trauma often want to try everything. They read about ayahuasca, ibogaine, San Pedro, psilocybin, and Kambo in the same forums, and they assume the safety profiles are roughly comparable. They aren't. Each has its own cardiovascular risks, drug interactions, and contraindications. Kambo specifically has been linked to fatal cardiac events in people with undiagnosed heart conditions, and the volume of water participants are encouraged to drink beforehand has caused fatal hyponatremia in at least one documented case. If you're researching plant medicine seriously, treat each substance as its own decision. The fact that ayahuasca worked beautifully for someone's depression tells you almost nothing about whether Kambo is safe for you. The Lechner inquest is a checklist of what not to accept. If you're considering a ceremony — Kambo or otherwise — these are the questions that actually matter: None of these are unreasonable questions. A good facilitator will welcome them. The ones who get defensive are telling you something. There's a tendency in the broader psychedelic and master plants space to close ranks when something goes wrong. The reasoning runs: regulators are circling, the medicine works, don't give them ammunition. I understand the instinct and I think it's the wrong instinct. The cases that go badly — Lechner's, the deaths during ibogaine treatments, the ayahuasca tragedies that occasionally make headlines — almost always involve preventable failures. Insufficient screening. Untrained facilitators. Mixing substances. Missing emergency protocols. Lone-wolf practitioners operating without peer accountability. If the community wants plant medicine to be taken seriously as a healing modality, including for addiction recovery and trauma, the work is to raise standards from inside, not to circle the wagons every time something goes wrong. For seekers, the takeaway is more personal. The fact that something is plant-based, traditional, or spiritually framed doesn't make it safe. Aspirin is plant-based. Hemlock is traditional. The same medicines that change lives can kill people when they're handled carelessly. Doing your own due diligence isn't an insult to the medicine. It's how you actually honor it. Start by getting clear on what you're actually hoping to address. Is it addiction? Depression? Unresolved trauma? A sense that something in your life has stopped moving? Different substances and different settings suit different problems. Ayahuasca tends to be the choice for deep emotional and psychological work over multiple ceremonies. Ibogaine has the strongest case for opioid addiction interruption. Psilocybin has the most established research base for depression and end-of-life anxiety. Kambo sits in a more peripheral place — useful, some say, as a complement, but rarely the centerpiece. Then get a full medical workup. Heart, liver, kidneys, blood pressure, current medications. Bring those results into your conversations with any potential retreat or practitioner. Ask about their screening process, their on-site or on-call medical support, their integration aftercare, and what they do when something goes wrong. The best operators have thought about this in detail and will tell you exactly. For readers who want to take this further, a range of vetted plant medicine and psychedelic retreats can be browsed on our marketplace here — useful as a starting point for comparing what reputable programs actually look like, what they screen for, and how they handle aftercare. Natasha Lechner was, by her friend's account, the kind of person everyone leaned on. The “Mamma Bear” of her circle. She loved music, books, and learning new things. She wasn't reckless. She was a person doing what a lot of curious, well-intentioned people are doing right now: looking for something that traditional Western medicine wasn't giving her. The tragedy isn't that she explored. It's that the people around her hadn't done the work to keep her safe. Don't let that be the story of your ceremony.
Integrating an Iboga Experience: What Actually Happens After the Ceremony
Most people walk into an iboga ceremony bracing for the experience itself — the long hours, the visions, the physical weight of the medicine pressing them into the mat. What almost no one prepares for is what comes after. The ceremony ends. You go home. And then? Then the actual work starts. Iboga, the root bark from a small West African shrub used for centuries in Bwiti tradition, is one of the most demanding plant medicines on the planet. It's also one of the most studied for addiction recovery — particularly opioid dependency. But here's the thing nobody at the retreat will quite tell you straight: the medicine doesn't fix you. It shows you. What you do with what it shows you is the entire ballgame. There's a tempting story floating around the psychedelic healing space — that one heroic dose will rewire your brain, dissolve your addiction, and hand you back a new life. People do report dramatic shifts after iboga, especially around opioid cravings. That part is real. What gets glossed over is the window. After a flood dose of ibogaine or traditional iboga root bark, many people describe a period — sometimes called the gray day, sometimes stretching into weeks — where old cravings are quiet, old patterns feel optional, and the mind is unusually pliable. This isn't a permanent state. It's an opening. Treat it like a runway, not a destination. Without integration, that window closes and the old grooves reassert themselves. With integration, you can build new grooves while the soil is soft. The difference between people who hold their gains and people who relapse within six months is almost always what they did between week one and month six. Right after an iboga experience, you may feel clear in a way you haven't felt in years. Clean. Lucid. Convinced that everything has changed. That feeling is partly real and partly a chemical afterglow, and it's a terrible time to make big decisions. People in this phase quit jobs, end relationships, move countries, announce sweeping life pivots — and a fair number regret it three months later when the high tide of insight has receded and they're left looking at the wreckage. The medicine showed you something true, probably. But truth and timing are different animals. Move slowly. Eat real food. Walk outside. Write things down before you forget them, because you will forget them. Integration isn't a mystical process. It's mostly mundane, daily, and a bit boring — which is exactly why people skip it. Here's what tends to work, drawn from what facilitators and people who've sustained their changes actually do. For the first week, sit down every morning and write whatever you remember. Visions, conversations with whatever you encountered, body sensations, names of people who appeared, regrets that surfaced. Don't edit. Iboga insights have a strange half-life — vivid for ten days, then they start dissolving. The journal is your archive. Talking to people who haven't done plant medicine about a plant medicine experience is mostly frustrating. They'll either be politely baffled or quietly worried about you. Find one person — a facilitator who offers integration calls, a therapist trained in psychedelic integration, a peer from your retreat — who can hear what you're saying without translating it into something smaller. One real conversation beats ten polite ones. Iboga tends to show people a long list of things that aren't working. Trying to fix all of them at once is how people burn out and end up back where they started. Choose one. Maybe it's the relationship you keep avoiding. Maybe it's the substance you keep returning to. Maybe it's the work schedule that's been quietly killing you. One thing, attacked seriously, will do more for you than ten things attacked half-heartedly. Iboga is a deeply somatic medicine — it lives in the body for a long time, and the insights it surfaces are often stored in the body too. Some kind of regular physical practice helps the integration land: walking, swimming, yoga, breathwork, simple stretching. Nothing extreme. The goal is to stay in contact with yourself, not to optimize a fitness routine. Ibogaine has a serious track record in interrupting opioid dependency. Clinics in Mexico, Costa Rica, and a handful of other jurisdictions have been treating heroin and prescription opioid addiction with it for decades, and the published outcomes are interesting enough that mainstream addiction medicine is finally paying attention. But interrupting is not the same as curing. What ibogaine seems to do reliably is take away the acute withdrawal and reset cravings for a window of time. What it cannot do is rebuild the life you'll re-enter once that window opens. If you go back to the same apartment, the same friends, the same patterns, the same unaddressed trauma — the addiction will find its way home. The people who stay clean after iboga are almost always the ones who treated the medicine as the start of a long process, not the end of a short one. This is why reputable iboga providers increasingly insist on aftercare programs, sober living arrangements, and structured follow-up. If you're considering iboga for addiction and the retreat you're looking at doesn't ask hard questions about your plan for the weeks after — that's a red flag worth paying attention to. A few patterns show up over and over with people who lose ground after an iboga journey: Iboga can surface old material — trauma, grief, suppressed memories — that doesn't always tuck itself back in neatly. Most people handle the unpacking with journaling, peer support, and time. Some people need more, and there's no shame in that. If you're experiencing prolonged sleep disruption past a few weeks, intrusive memories that won't settle, depressive episodes deeper than your baseline, or thoughts of self-harm, that's the moment to find a therapist — ideally one familiar with psychedelic integration, though a competent trauma therapist of any stripe is better than going it alone. Iboga can crack things open that need a professional hand to help close. Plant medicine doesn't replace mental health care. At its best, it accelerates and deepens the work. At its worst, it surfaces things you weren't ready to face. Knowing the difference, and being willing to ask for help, is part of being a serious participant in your own healing. People who've held their iboga insights five and ten years later describe something interesting: the experience itself becomes less central over time, but the small daily decisions they made in the months after — the boundary they finally drew, the job they finally left, the practice they finally committed to — those compound. The ceremony was a doorway. The life on the other side was built one ordinary week at a time. That's the part the brochures don't sell well, because it isn't dramatic. But it's the part that matters. If you're seriously considering iboga for addiction, depression, or a stuck pattern you can't seem to shake, the question to sit with isn't whether the medicine will work. It's whether you're prepared to do the slow, unglamorous work that makes the medicine stick. For readers who want to take this further, a range of carefully vetted iboga and ibogaine retreats can be browsed on our marketplace here. The plant will do its part. The rest is yours.
Why Silicon Valley Founders Are Flying to Peru for Ayahuasca Ceremonies
Somewhere in the Sacred Valley of Peru, between Cusco and Machu Picchu, an adobe temple sits on a ridge overlooking the Andean highlands. Inside, a group of founders — people who normally spend Tuesday mornings arguing about runway and burn rate — are lying on thin mats, waiting for a brew of bitter brown liquid to start dismantling everything they think they know about themselves. This is what an ayahuasca retreat for tech entrepreneurs actually looks like. And it costs roughly the price of a decent used car. The trend isn't new anymore — it's been simmering for over a decade — but the questions around it have only sharpened. Why are so many high-functioning, ambitious people turning to plant medicine? What does it actually do? And is it a legitimate tool for working through stuck patterns, including addiction and burnout, or just the latest expensive thing successful people do to feel something? I've sat in enough ceremonies and interviewed enough facilitators to have opinions on all of that. Let's get into it. The pattern goes back further than most people realize. Steve Jobs talked about LSD as one of the most important experiences of his life. Bill Gates dabbled. Tim Ferriss has been openly discussing psychedelics for years, once comparing ayahuasca in tech circles to grabbing coffee. That's an overstatement — you're not going to find anyone microdosing DMT between standups — but the cultural underground is real. What changed around the mid-2010s was the appearance of structured programs aimed specifically at founders and executives. One of the better-known ones runs small cohorts to Peru each year — usually around 20 people split across two trips, drawn from hardware, software, and fintech startups. The price tag tends to land between $10,000 and $12,000 once you factor in coaching, lodging, ceremony, and the long-haul flights. The founder of one such program once put it bluntly to a reporter: you can spend six years in therapy, or you can spend ten days in the Andes. Red pill or sugar pill? It's a great soundbite. It's also, in my honest opinion, only half true. More on that later. The brew itself is made from the Banisteriopsis caapi vine, often combined with chacruna leaves that contain DMT. Indigenous peoples across the Amazon have been working with this combination for centuries — some traditions say thousands of years — as part of healing and spiritual practice. It's legal in Peru and in a handful of other South American countries. In the United States it sits in a strange grey zone: DMT is Schedule I, but two religious organizations have won the right to use the brew sacramentally. A typical 10-day retreat tends to follow a rhythm something like this: Inside the ceremony itself, the experience varies wildly. Some people describe lucid-dream-like visions — wandering through landscapes, encountering animals, replaying childhood scenes. One past participant of a tech-focused retreat described witnessing himself as a boy in a humiliating moment from grade school and finally, at age forty-something, deciding to put the shame down. Another described leaving her body entirely and watching herself from across the room. A friend of mine swears he spent two hours moving through what he insists was the inside of his own digestive tract, like a deranged children's TV episode. And then there's the vomiting. Almost everyone purges. Practitioners call it cleansing; your body calls it Tuesday. A well-run ayahuasca ceremony has buckets, towels, and absolutely no judgment about any of it. This is the question that brings most thoughtful people to plant medicine in the first place — and it deserves a careful answer. There's a growing body of clinical and observational research suggesting that ayahuasca, psilocybin, and ibogaine can produce meaningful, sometimes durable shifts in people struggling with depression, PTSD, alcohol use disorder, and opioid dependence. Ibogaine in particular has a long track record with opioid addiction — it appears to reset some of the neurochemistry involved in withdrawal and craving. Ayahuasca's effects on addiction seem to work through a different door: not by interrupting the chemistry directly, but by surfacing the emotional material that drives the behavior in the first place. That said — and this matters — psychedelics are not magic. They don't do the work for you. What they do is create an unusual window in which patterns become visible, often painfully so. What you do with that visibility afterward is the actual healing. Facilitators have a word for this: integration. It's the part where you come home, talk through what surfaced with a therapist or coach or trusted friend, and start translating insight into different daily behavior. Skipping integration is the most common mistake I see. People take the trip, have a profound night, fly home, and then six months later wonder why nothing actually changed. The ceremony was the easy part. Let's talk honestly about money, safety, and quality — because this is where retreat-seekers most often get burned. Costs for a reputable ayahuasca retreat in Peru typically range from about $1,500 for a basic week with a local center to $11,000 or more for a high-touch program with executive coaching wrapped around it. Neither extreme is automatically better. I've sat in ceremonies at modest centers run by lineage shamans that were more rigorous and more healing than fancy operations with infinity pools. Price signals nothing in this world. What you actually want to evaluate: The unflattering nickname for sloppy, poorly run ceremonies is “yogahuasca” — a Bay Area knockoff aesthetic stapled onto a sacred practice. The problem isn't confined to California either. As demand has exploded, some operations in Peru have followed the money rather than the lineage. Caveat emptor applies, hard. Plant medicine isn't for everyone, and I'd argue strongly against the “hack your consciousness” framing that tech culture sometimes wraps around it. This isn't a shortcut. It's a serious encounter with your own mind, and the people who get the most from it tend to share a few traits. They've usually tried other things first — therapy, meditation, hard conversations, time off. They have a baseline of psychological stability and aren't in active crisis. They have someone to talk to when they get home. They approach the experience with respect rather than treating it as a novelty item to collect alongside Burning Man and a Wim Hof workshop. And critically, they're willing to sit with discomfort. Ayahuasca isn't fun. It's revelatory, sometimes beautiful, occasionally terrifying, and almost always physically rough. People who want pleasant trips should look elsewhere. The founders I've spoken to who report the most lasting benefit describe specific behavioral changes afterward — quitting jobs that were wrong for them, restructuring how they interact with employees, finally addressing a drinking habit, ending relationships that had been quietly dying for years. The shift isn't mystical. It's that the ceremony made a long-avoided truth impossible to ignore for one night, and they found the nerve to act on it. If you've read this far and you're still curious, a few practical suggestions before you book anything. Read at least three first-person accounts of difficult ceremonies, not just the glowing ones. Talk to someone who's been. If you're on prescription medication, especially antidepressants, consult with a doctor who actually understands plant medicine — not all of them do. Sit with the question of why you want to do this. “To see what it's like” is a fine answer for a wine tasting; it's a thin reason to invite an Amazonian vine into your nervous system for six hours. Give yourself a clear week on the back end with no major commitments. The landing is real, and trying to jump straight into a board meeting after a retreat is how people lose the insights they came for. Find a therapist or integration coach you trust, ideally before you go. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it carefully — this is one of those choices that tends to matter more in the months after than in the moment you book it.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
